By way of two resoundingly consistent votes, members of an FDA advisory committee agreed that PD-1 inhibitors do not have a favorable risk/benefit profile for gastroesophageal cancers with low PD-L1 ...

Olomorasib with pembrolizumab in the first-line showed a 77% overall response rate in patients with KRAS G12C–mutated ...

PD-1 inhibition before and after surgery for high-risk early triple-negative breast cancer (TNBC) led to significant ...

Merck & Co Inc (NYSE:MRK) released topline data from the KEYFORM-007 Phase 3 study of the fixed-dose combination of ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant ...

The FDA’s Oncologic Drug Advisory Committee voted against the use of checkpoint inhibitors in esophageal cancer with PD-L1 ...

NuCana plc (NASDAQ: NCNA) announced the issuance of a new patent by the United States Patent and Trademark Office (USPTO) covering NUC-7738’s composition of matter. This patent (US12,054,510) is ...

Pembrolizumab plus chemoradiotherapy improved survival in patients with previously untreated, high-risk locally advanced ...

Patients with locally advanced cervical cancer were randomized to receive either pembrolizumab or placebo in combination with ...

Pembrolizumab (Keytruda, Merck) has picked up another indication — this time for the first-line treatment of unresectable ...

Discover the results from the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study, presented at ESMO 2024, Barcelona, Spain ...

Key data readouts for the company’s late-stage, potentially registrational trials of nemvaleukin are expected in late Q1/early Q2 2025 for ...